Ovaprene phase 1: protocol finalization, regulatory approval, start-up, and commencement of recruitment, screening, and enrollment for the ovaprene vaginal device clinical trial
Ended Awarded Last action
- Contract number
- 75N94023F00001
- Awardee
-
Oregon Health & Science University UEI NPSNT86JKN51
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $68,637
Award facts
- Contract value 27% obligated
- $249,678.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 15 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Portland, OR 97239, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$1,804 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $70,441 | |
| Other Administrative Action | $0 | |
| Original award | $181,041 |
About this award
Oregon Health & Science University (OHSU) was awarded a $249,678 delivery order contract by the National Institute of Child Health and Human Development (NICHD) on September 28, 2023, for OVAPRENE Phase 1 clinical trial support. The work encompasses protocol finalization, regulatory approval, startup activities, and the commencement of recruitment, screening, and enrollment for the OVAPRENE vaginal device clinical trial. The contract is structured as cost-no-fee pricing with an ultimate completion date of May 31, 2025, and will be performed at OHSU's Portland, Oregon location. No set-aside designation was applied to this competitive award.
This delivery order supports NICHD's mission in contraceptive development and reproductive health research. OHSU, a prominent academic medical center and state-controlled research institution, brings substantial expertise in clinical trial management, regulatory navigation, and biostatistical support services. The institution has an established track record with NICHD, including prior work on contraceptive efficacy studies and central laboratory services, as well as extensive NIH-funded research portfolios in reproductive health outcomes, pregnancy-related research, and contraceptive efficacy evaluation. The non-severable contract structure ensures continuity through the critical early phases of the clinical trial.
Quick answers
Who was awarded contract 75N94023F00001?
75N94023F00001 was awarded to Oregon Health & Science University by National Institute of Child Health and Human Development (National Institutes of Health) on September 28, 2023.
How much is contract 75N94023F00001 worth?
The government has obligated $68,637 on 75N94023F00001. Its current value, with exercised options, is $249,678.
Is contract 75N94023F00001 an order under another contract?
Yes. 75N94023F00001 is a delivery order under 75N94020D00016, an indefinite delivery contract.
Was contract 75N94023F00001 competed?
The extent of competition for 75N94023F00001 was full and open competition. The government received 15 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award